Search
for
Sort by
Research
900-930 / 1000+ results
research Reduced Prostate Cancer Risk in Patients with Androgenetic Alopecia Using 5-Alpha Reductase Inhibitors: A TriNetX Real-World Cohort Study
Using 5-alpha reductase inhibitors may lower prostate cancer risk in people with androgenetic alopecia.
research QUALITY ASSESSMENT OF HERBAL MEDICINAL PRODUCTS IN BENIGN PROSTATE HYPERTROPHY: CHEMICAL MARKERS AND FINGERPRINT ANALYSIS
Herbal products for benign prostate hypertrophy need better quality checks to ensure safety and effectiveness.
research Morphological Changes of Meibomian Glands in Men With Benign Prostate Hyperplasia
Men with benign prostate hyperplasia have more meibomian gland loss and tear film problems.
research Re: Associations Between Variants in the Cyclooxygenase 2 Enzyme Gene (PTGS2) and Development of Benign Prostate Enlargement
Certain gene variants may raise the risk of prostate enlargement, but taking NSAIDs could reduce this risk.
research 342 COMPARISON OF THE INCIDENCE OF SECONDARY CANCERS AFTER IMRT, BRACHYTHERAPY AND SURGERY FOR THE TREATMENT OF PROSTATE CANCER
Different prostate cancer treatments have similar risks of secondary cancers and related mortality when considering patient age and smoking history.
research 1452 DETECTION RATE OF CLINICALLY INSIGNIFICANT PROSTATE CANCER INCREASES WITH REPEATING PROSTATE BIOPSIES
More prostate biopsies increase the chance of finding cancers that may not need treatment.
research IMPACT OF LOW DOSE FINASTERIDE FOR THE TREATMENT OF ANDROGENIC ALOPECIA ON SERUM PROSTATE SPECIFIC ANTIGEN (PSA) LEVELS IN MEN PARTICIPATED IN POPULATION-BASED SCREENING FOR PROSTATE CANCER
Low dose finasteride causes only minor changes in PSA levels in men over 50 with BPH.
research Are PSA adjustments necessary for prostate cancer screening in men taking finasteride for hair loss?
Finasteride for hair loss lowers PSA levels, so PSA values need adjusting when screening for prostate cancer.
research Estudio clínico-patológico sobre el cáncer de próstata incidental en pacientes intervenidos bajo el supuesto diagnóstico de HBP sintomática
Incidental prostate cancer was found in 4.89% of patients undergoing surgery for benign prostatic hyperplasia.
research Serum prostate spesific antigen levels in women with androgenetic alopecia
Women with androgenetic alopecia (hair loss) have normal prostate specific antigen levels but higher testosterone levels.
research Androgen biosynthetic pathways in the human prostate
DHT in the human prostate is produced through multiple pathways, not just from testosterone.
research Risk factors for prostate cancer: a case-control study in Greece
Urban living may increase prostate cancer risk, while early sexual activity might reduce it.
research Wedelolactone, a medicinal plant-derived coumestan, induces caspase-dependent apoptosis in prostate cancer cells via downregulation of PKCε without inhibiting Akt
Wedelolactone selectively kills prostate cancer cells without harming normal cells.
research Doxil (Caelyx): an exploratory study with pharmacokinetics in patients with hormone-refractory prostate cancer
Doxil showed some effectiveness against advanced prostate cancer but caused severe side effects at higher doses.
research The Dark Side of 5α-Reductase Inhibitors' Therapy: Sexual Dysfunction, High Gleason Grade Prostate Cancer and Depression
5α-reductase inhibitors can cause sexual problems, higher risk of aggressive prostate cancer, and depression.
research Novel Anti-Prostate Cancer Curcumin Analogues That Enhance Androgen Receptor Degradation Activity
New curcumin analogues help fight prostate cancer by breaking down androgen receptors.
research Finasteride Inhibits Human Prostate Cancer Cell Invasion through MMP2 and MMP9 Downregulation
Finasteride may reduce prostate cancer spread by lowering certain enzyme levels.
research Redefining hormone resistance in prostate cancer
The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.
research Estimating the Contribution of the Prostate to Blood Dihydrotestosterone
The normal human prostate does not significantly affect blood DHT levels.
research Epidemiological study of prostate cancer (EPICAP): a population-based case–control study in France
Circadian rhythm disruption, chronic inflammation, hormones, metabolism, and genetics may increase prostate cancer risk.
research Androgenetic alopecia and prostate cancer: findings from an Australian case-control study.
The conclusion is that there might be a link between certain types of baldness and prostate cancer, which could be due to shared hormonal pathways.
research Recent discoveries and developments of androgen receptor based therapy for prostate cancer
New treatments for prostate cancer are less toxic and show promise, but more research is needed to enhance their effectiveness and reduce side effects.
research Risk factors for prostate cancer: a case‐control study in Greece
Urban living may increase prostate cancer risk, while early sexual activity might reduce it.
research Clinical Management of Prostate Cancer in High-Risk Genetic Mutation Carriers
More research and guidelines are needed for managing prostate cancer in people with high-risk genetic mutations.
research Impact of Medical Castration on Malignant Arrhythmias in Patients With Prostate Cancer
Medical castration in prostate cancer patients can increase the risk of serious heart rhythm problems, so it's important to monitor heart activity during treatment.
research The influence of Castanea sativa Mill. flower extract on hormonally and chemically induced prostate cancer in a rat model
Chestnut flower extract may help reduce prostate cancer growth.
research Genetic variants in AR and SHBG and resistance to hormonal castration in prostate cancer
Certain genetic variants increase the risk of resistance to hormone therapy in prostate cancer patients.
research Diabetes Mellitus and Prostate Cancer Risk—A Systematic Review and Meta-Analysis
Diabetes may lower the risk of prostate cancer.
research RE: EFFECT OF THE DUAL 5α-REDUCTASE INHIBITOR DUTASTERIDE ON MARKERS OF TUMOR REGRESSION IN PROSTATE CANCER
Dutasteride may help shrink prostate cancer tumors.